Free tool
FAERS Monitor: Uplizna
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761142 or its brand name (Uplizna, Inebilizumab-Cdon). Reports on generic versions are filed under their own applications.
Reports
858
Serious
625
73% of reports
Hospitalization
303
Death reported
53
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neuromyelitis optica spectrum disorder130
- off label use76
- headache50
- urinary tract infection44
- fatigue39
- nausea38
- myasthenia gravis37
- pneumonia36
- covid-1932
- pain31
- arthralgia25
- death23
- pyrexia23
- infection21
- hypoaesthesia20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 21 |
| 2021 | 79 |
| 2022 | 22 |
| 2023 | 50 |
| 2024 | 143 |
| 2025 | 161 |
| 2026 | 382 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,301 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neuromyelitis optica spectrum disorderSignal | 130 | 2616.8 | 2212.1 | 304,828 |
| myasthenia gravisSignal | 37 | 112.8 | 82.2 | 3,973 |
| urinary tract infectionSignal | 44 | 6.3 | 4.7 | 193 |
| covid-19Signal | 32 | 4.5 | 3.2 | 83 |
| infectionSignal | 21 | 3.6 | 2.3 | 36 |
| hypoaesthesiaSignal | 20 | 3.3 | 2.1 | 30 |
| pneumoniaSignal | 36 | 2.7 | 2.0 | 38 |
| off label useSignal | 76 | 2.1 | 1.7 | 46 |
| headache | 50 | 2.0 | 1.5 | 23 |
| pyrexia | 23 | 1.6 | 1.1 | 5 |
| arthralgia | 25 | 1.5 | 1.0 | 3 |
| pain | 31 | 1.2 | 0.9 | 1 |
| fatigue | 39 | 1.2 | 0.9 | 1 |
| nausea | 38 | 1.2 | 0.9 | 1 |
| death | 23 | 0.7 | 0.4 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.